Wockhardt LtdQ4 FY24Pharmaceuticals & Biotechnology

Wockhardt Ltd

Q4 FY24 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Diabetes portfolio (insulin, glargine) in emerging markets expected to drive large growth; current presence ~$50 million with a covered market of $1.5 billion.
→Emerging markets including Latin America, Asia, Russia CIS, and growing MENA region showing improvement and growth.
→UK business growing with increased market share and aggressive product filings (23 filed since 2020, 24 more in next two years).
→Vaccine business with Serum collaboration expected to be a game changer, with reserved 150 million doses capacity and sustained increasing business and profitability.
→Biologicals and biosimilars to grow faster than generics; biologics revenue expected to increase from 20% to 30% of total in next 2-3 years.
→New product launches planned: 14 in India and 25 in UK during 2024-25, including insulin Aspart and other diabetes-related launches.
→US sales maintained via third-party manufacturing, expecting ~40% gross margin with reduced losses.
→Overall growth momentum positive and expected to accelerate in coming years.

Margin guidance

Category 1

→The US business restructuring is expected to cut losses by approximately USD 10 million, improving bottom-line profitability and aiming for about 40% overall margin in US operations.
→The US business, previously a financial drain, is expected to turn profitable within two years.
→Biologics and biosimilars currently contribute ~20% of revenue, projected to increase to ~30% in 2-3 years, driving faster growth.
→The company targets positive PBT (Profit Before Tax) and cash EBITDA growth by FY24 and significant profitability improvements in FY25.
→New product launches in India, UK, Latin America, MENA, and emerging markets will contribute to revenue growth.
→Total clinical trial investment for WCK 5222 estimated at USD 30 million, funded by alternate sources without impacting cash flow.
→Emphasis on R&D, new drug discovery, and vaccine collaborations (Serum deal) expected to bolster margins and growth.
→Overall, management is positive on accelerating profitable growth and improved financial health over the next 2-3 years.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Wockhardt Ltd and 1,400+ other companies.

Fundraise plans

Yes

→Wockhardt intends to seek external funding primarily for its ongoing clinical trial of WCK 5222, requiring about USD 30 million over the next 12 to 15 months.
→The funding approach includes alternate sources such as debt funding and monetization of non-core assets.
→No specific new equity fundraising is mentioned, but promoter commitment has increased significantly over recent years, with promoter loans converted into equity and additional funds raised via a rights issue in the past.
→For CapEx, apart from clinical trials, there are no manufacturing-related CapEx requirements because manufacturing is outsourced to FDA-approved facilities.
→Overall, they aim to fund R&D and clinical trials through a mix of cash flow, debt, and asset monetization without heavily relying on operating cash flow.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Wockhardt Ltd. However, some relevant points indicating business prospects and volumes include: - Serum deal guarantees a certain minimum quantity of vaccine doses post-initial phase with expected high margin per dose. - Company aims to achieve vaccine production of 150 million doses per annum through collaboration with Serum. - Product launches planned: 14 in India and 25 in the UK during FY24-25. - Continuous filings and launches in emerging markets with focus on biologicals and biosimilars to grow from 20% to 30% revenue contribution in 2-3 years. - Clinical trials ongoing for WCK 5222 with global enrollment, intending completion in 15-18 months, supporting future product approvals. - Manufacturing in US and Canada shifted to third-party companies to improve margins and maintain sales volume. No direct numeric values on pending order backlog were disclosed.

Capex plans

Yes

→Planned CapEx of approximately USD 30 million primarily to complete the clinical trial for WCK 5222 (Page 12, 7).
→No manufacturing CapEx required for WCK 5222 as production is outsourced to FDA-approved European facilities (Page 12).
→Restructuring of US business includes shutting down own manufacturing in Morton Grove, shifting to third-party manufacturing, resulting in savings of about USD 12 million annually (Page 3).
→Ongoing strategic collaboration with Serum for vaccine manufacturing in the UK to drive growth (Page 6).
→Investment focus on R&D, particularly biological and drug discovery, maintaining 8-9% of revenue for R&D with shifting priority from pharmaceutical to biological R&D (Page 9).
→Exploring alternate funding sources including debt funding and asset monetization for clinical trial and R&D investments (Page 7).

How does Wockhardt Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Wockhardt Ltd

Rev 2Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Unlock with Pro

Want more stocks like Wockhardt Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio